Company intelligence / Profile preview

Turn Biotechnologies

Mountain View, California, United Statesturn.bio ↗

Ownership: Private
Employees: ~50
Development stage: Preclinical

Overview

Turn Bio is advancing pre-clinical research for multiple indications including dermatology and immunology applications. Their lead candidate TRN-001 for skin rejuvenation uses the eTurna platform, while other candidates for ophthalmology and immune cell rejuvenation are being developed with the recently acquired ARMMs technology. The company hopes to advance to clinical trials in 2023 as mentioned in earlier reports[8].

Therapeutic areas: Metabolic DisordersImmunologyOtherDermatologyRheumatologyOphthalmology
Modalities: mRNA-based therapiesepigenetic reprogramming
Industry: Biotech

Drug pipeline

9 assets

TRN-001

Preclinical

8 more assets in the full pipeline.

Request access →

Partnerships

HanAll BiopharmaAstellas Venture ManagementDaewoong Pharmaceuticals

Beyond the preview

Go deeper on Turn Biotechnologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Turn Biotechnologies.

Explore the full profile